Lifeward Ltd. announced its financial results for the fourth quarter and full year ended December 31, 2024, on March 7, 2025. The company reported record quarterly revenue of $7.5 million in Q4 2024, a 10% increase from $6.9 million in Q4 2023, and record annual revenue of $25.7 million for the full year 2024.
Revenue from AlterG products and services grew by 17% to $5.5 million in Q4 2024, driven by strong international demand. However, revenue from ReWalk exoskeletons, MyoCycles, and ReStore Exo-Suits decreased by 6% to $2.0 million due to scheduling challenges and delays for initial training sessions.
The company reported a GAAP net loss of $15.3 million, or $1.73 per share, for Q4 2024. As of December 31, 2024, Lifeward had $6.7 million in cash and cash equivalents. For 2025, Lifeward expects full-year revenue between $28 million and $30 million, adjusted gross margins of 47% to 49%, and anticipates achieving an adjusted operating loss of approximately $1 million by the fourth quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.